Clinical activity of MCLA-128 (zenocutuzumab), trastuzumab, and vinorelbine in HER2 amplified metastatic breast cancer (MBC) patients (pts) who had progressed on anti-HER2 ADCs.-MedSci.cn

Clinical activity of MCLA-128 (zenocutuzumab), trastuzumab, and vinorelbine in HER2 amplified metastatic breast cancer (MBC) patients (pts) who had progressed on anti-HER2 ADCs.

Hamilton, EP; Petit, T; Pistilli, B; Goncalves, A; Ferreira, AA; Dalenc, F; Cardoso, F; Mita, MM; Dezentj, VO; Manso, L; Graff, SL; Bidard, FC; Aftimos, PG; Escriv, S; Afonso, N; Wasserman, E; Bol, K; Stalbovskaya, V; Vliet, A; Bachelot, T

JOURNAL OF CLINICAL ONCOLOGY, 2020; 38 (15):

科室
- - 订阅+
  - 更多科室
工具
服务